Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Baraniskin A, Munding J, Schulmann K, Meier D, Porschen R, Arkenau HT, Graeven U, Schmiegel W, Tannapfel A, Reinacher-Schick A. Baraniskin A, et al. Clin Colorectal Cancer. 2011 Mar 1;10(1):24-9. doi: 10.3816/CCC.2011.n.003. Clin Colorectal Cancer. 2011. PMID: 21609932
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.
Reinacher-Schick A, Schulmann K, Modest DP, Bruns N, Graeven U, Jaworska M, Greil R, Porschen R, Arnold D, Schmiegel W, Tannapfel A. Reinacher-Schick A, et al. BMC Cancer. 2012 Aug 9;12:349. doi: 10.1186/1471-2407-12-349. BMC Cancer. 2012. PMID: 22876876 Free PMC article. Clinical Trial.
Amphiphysin-positive paraneoplastic myelitis and stiff-person syndrome.
Faissner S, Lukas C, Reinacher-Schick A, Tannapfel A, Gold R, Kleiter I. Faissner S, et al. Neurol Neuroimmunol Neuroinflamm. 2016 Sep 28;3(6):e285. doi: 10.1212/NXI.0000000000000285. eCollection 2016 Dec. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 27734022 Free PMC article. No abstract available.
Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.
Noepel-Duennebacke S, Arnold D, Hertel J, Tannapfel A, Hinke A, Hegewisch-Becker S, Reinacher-Schick A. Noepel-Duennebacke S, et al. Clin Colorectal Cancer. 2018 Dec;17(4):e733-e739. doi: 10.1016/j.clcc.2018.07.007. Epub 2018 Jul 25. Clin Colorectal Cancer. 2018. PMID: 30145148 Clinical Trial.
Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.
Stintzing S, Ivanova B, Ricard I, Jung A, Kirchner T, Tannapfel A, Juette H, Hegewisch-Becker S, Arnold D, Reinacher-Schick A. Stintzing S, et al. Front Oncol. 2018 Nov 8;8:474. doi: 10.3389/fonc.2018.00474. eCollection 2018. Front Oncol. 2018. PMID: 30467535 Free PMC article.
166 results